FI54916C - FRAMEWORK FOR THERAPEUTIC TREATMENT OF NUTRITIONAL N-SUBSTITUTE 2-PYRROLIDONER - Google Patents

FRAMEWORK FOR THERAPEUTIC TREATMENT OF NUTRITIONAL N-SUBSTITUTE 2-PYRROLIDONER

Info

Publication number
FI54916C
FI54916C FI383/71A FI38371A FI54916C FI 54916 C FI54916 C FI 54916C FI 383/71 A FI383/71 A FI 383/71A FI 38371 A FI38371 A FI 38371A FI 54916 C FI54916 C FI 54916C
Authority
FI
Finland
Prior art keywords
pyrrolidoner
nutritional
substitute
framework
therapeutic treatment
Prior art date
Application number
FI383/71A
Other languages
Finnish (fi)
Other versions
FI54916B (en
Inventor
Joseph Honore Lucien M Strubbe
Raymond Armand Linz
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of FI54916B publication Critical patent/FI54916B/en
Application granted granted Critical
Publication of FI54916C publication Critical patent/FI54916C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI383/71A 1970-02-13 1971-02-10 FRAMEWORK FOR THERAPEUTIC TREATMENT OF NUTRITIONAL N-SUBSTITUTE 2-PYRROLIDONER FI54916C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB697870A GB1309692A (en) 1970-02-13 1970-02-13 N-substituted lactams

Publications (2)

Publication Number Publication Date
FI54916B FI54916B (en) 1978-12-29
FI54916C true FI54916C (en) 1979-04-10

Family

ID=9824325

Family Applications (1)

Application Number Title Priority Date Filing Date
FI383/71A FI54916C (en) 1970-02-13 1971-02-10 FRAMEWORK FOR THERAPEUTIC TREATMENT OF NUTRITIONAL N-SUBSTITUTE 2-PYRROLIDONER

Country Status (15)

Country Link
JP (2) JPS535301B1 (en)
BE (1) BE762728R (en)
CH (1) CH530395A (en)
CS (2) CS167911B2 (en)
DE (1) DE2106418C2 (en)
DK (1) DK137451B (en)
ES (1) ES388135A2 (en)
FI (1) FI54916C (en)
FR (1) FR2081508B2 (en)
GB (1) GB1309692A (en)
MY (1) MY7400072A (en)
NL (1) NL168830C (en)
SU (2) SU508186A3 (en)
YU (2) YU34876B (en)
ZA (1) ZA71877B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1045043B (en) * 1975-08-13 1980-04-21 Isf Spa PYROLIDINE DERIVATIVES
GB1583871A (en) 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
BE864269A (en) * 1977-03-03 1978-06-16 Parke Davis & Co NEW N- (AMINOALKYL SUBSTITUTE) -2-OXO-1-PYRROLIDINE-ACETAMIDES AND METHODS FOR PRODUCING THEM
EP0005689B1 (en) * 1978-05-08 1981-03-18 U C B, S.A. Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
IT1141287B (en) * 1979-06-13 1986-10-01 Nattermann A & Cie PYROLIDIN ACIDS AMIDS- (2) -ON- (1) -ILALKYL-CARBOXYLS, PROCEDURE FOR THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THEM
FR2515179A1 (en) * 1981-07-24 1983-04-29 Hoffmann La Roche PYRROLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES FOR THEIR SYNTHESIS AND THEIR THERAPEUTIC APPLICATION
EP0089900B1 (en) * 1982-03-24 1985-12-27 Prodes S.A. New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
DE3420193A1 (en) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim NEW SUBSTITUTED PYRROLIDINONES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
US4804400A (en) * 1986-09-12 1989-02-14 Ciba-Geigy Corporation N-phenyl-maleimides and herbicidal and plant growth regulating methods of use thereof
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
AR020115A1 (en) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co THERAPEUTIC OR PREVENTIVE AGENT FOR REBEL EPILEPSIES AND USE OF THE COMPOUND FOR THE SAME PRODUCTION
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ATE410412T1 (en) * 2001-08-10 2008-10-15 Ucb Pharma Sa OXOPYRROLIDINE COMPOUNDS, METHOD FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PRODUCING LEVETIRACETAM AND ANALOGUES
JP4351909B2 (en) * 2001-10-08 2009-10-28 ユセベ ファルマ ソシエテ アノニム Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a medicament
CA2515090A1 (en) 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd Process for producing levetiracetam
ES2214147B1 (en) 2003-02-28 2005-10-01 Farma-Lepori S.A. PROCEDURE FOR OBTAINING AN ANTIEPILEPTIC AGENT.
CA2497062A1 (en) 2004-02-18 2005-08-18 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
US20080146819A1 (en) * 2005-03-10 2008-06-19 Rubamin Limited Process for Preparing Levetiracetam
JP2008542323A (en) 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム 2-Oxo-1-pyrrolidine derivatives, process for producing the same and use thereof
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
DK2346500T3 (en) 2008-10-16 2017-07-17 Univ Johns Hopkins Methods and compositions for improving cognitive function
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
EA202092673A3 (en) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins Methods and compositions for improving cognitive function
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
PL3096790T3 (en) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ME03518B (en) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN104059010A (en) * 2014-06-12 2014-09-24 浙江华海药业股份有限公司 Preparation method of 2-(2-oxopyrrolidine-1-yl)-butyrate
CN106591179B (en) * 2016-12-05 2018-07-03 长兴制药股份有限公司 Methyl packing bacterium and its prepare the application on (S)-α-ethyl -2- oxygen -1- pyrrolidine acetic acid salt in selective fractionation
RU2663899C1 (en) * 2017-07-19 2018-08-13 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Process for the preparation of 1-carbamoylmethyl-4-phenyl-2-pyrrolidone
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) * 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams

Also Published As

Publication number Publication date
FI54916B (en) 1978-12-29
ES388135A2 (en) 1973-05-01
DE2106418C2 (en) 1983-12-22
YU34876B (en) 1980-04-30
SU508185A3 (en) 1976-03-25
SU508186A3 (en) 1976-03-25
FR2081508B2 (en) 1975-06-06
DK137451C (en) 1978-07-24
CH530395A (en) 1972-11-15
NL168830C (en) 1982-05-17
CS167912B2 (en) 1976-05-28
FR2081508A2 (en) 1971-12-03
JPS535301B1 (en) 1978-02-25
YU30671A (en) 1979-10-31
ZA71877B (en) 1971-10-27
BE762728R (en) 1971-08-10
JPS5420491B2 (en) 1979-07-23
DK137451B (en) 1978-03-06
JPS53130656A (en) 1978-11-14
GB1309692A (en) 1973-03-14
CS167911B2 (en) 1976-05-28
NL168830B (en) 1981-12-16
DE2106418A1 (en) 1971-08-19
MY7400072A (en) 1974-12-31
NL7101697A (en) 1971-08-17
YU144578A (en) 1982-10-31

Similar Documents

Publication Publication Date Title
FI54916C (en) FRAMEWORK FOR THERAPEUTIC TREATMENT OF NUTRITIONAL N-SUBSTITUTE 2-PYRROLIDONER
SE387861B (en) APPARATUS FOR EVAPORATION TREATMENT OF VETSKOR
SE393381B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF 8-AZAPURIN - 6 - UNDERIVATIVES
FI54301C (en) FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC KINAZOLINDERIVAT
SE390304B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF 4-HYDROXY-5-ETHYL-6-PHONYLPYRIMIDINE
SE384529B (en) APPLIANCE FOR TREATMENT OF ANIMAL SKIN OR SIMILAR
FI55184B (en) PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC VERKSAMY PHENYL-2-PYRROLIDINONER SAMT DERAS ISOMERER
SE388422B (en) PROCEDURE FOR REDUCTION OF THEABIN
BE776863A (en) REDISTRIBUTION OF ALKYLHYDROSILANES
FI54100C (en) FRAMEWORK FOR THERAPEUTIC TREATMENT OF THERAPEUTIC TRICYCLES
DOP1971001881A (en) TREATMENT OF TEETH
FI54104C (en) FRAMEWORK FOR THERAPEUTIC TREATMENT
FI54602B (en) FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC THERAPY OF 6-AMIDINOPENICILLANSYRADERIVAT
FI55988C (en) REFERENCE FOR THERAPEUTIC USE OF THERAPEUTIC THERAPEUTIC O-ACYLPHENOLETHANOLAMINER
FI53967C (en) FRAMEWORK FOR THERAPEUTIC ADJUSTMENT OF THERAPEUTIC BENSOBICYCLOALKANAMINER
FI55503C (en) FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC ANIMAL THERMAL PYRIMIDINONDERIVAT
SE384142B (en) TREATMENT CHAMBER
FI53700C (en) FRAMEWORK FOR THE ADMINISTRATION OF THERAPEUTIC THERAPEUTIC DIAMINOPROPIOFENONDERIVAT
FI53819C (en) FORMULATION OF NUTRITIONAL THERAPEUTIC NUTRITIONAL N-LYSERGYL-3-AMINOPYRIDINER
FI55338B (en) PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC VERIFICATION N-METHYL IMIDAZOLER
SE382051B (en) PROCEDURE FOR PREPARATION OF 3-SULPHONAMIDE-4-HYDROXYPHENYL-2-PIPERIDYLCARBINOLS
FI56171B (en) FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC ACTIVATED ACYLES
FI56179C (en) ADJUSTMENT OF THERAPEUTIC FREQUENCY OF THERAPEUTIC
BE774241A (en) THERAPEUTIC PROCESS AND COMPOSITIONS
FI55172B (en) FRAMEWORK FOR THE PROCESSING OF THERAPEUTIC POLICY